Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: a large, field-practice study

BACKGROUND: The once-daily oral combination of daclatasvir (DCV) and sofosbuvir (SOF), with or without ribavirin (RBV), is effective and well tolerated in patients with hepatitis C virus (HCV). However, further field-practice studies are necessary to investigate the effectiveness and safety of the D...

Descripción completa

Detalles Bibliográficos
Autores principales: Sacco, Rodolfo, Messina, Vincenzo, Gentilucci, Umberto Vespasiani, Adinolfi, Luigi Elio, Ascione, Antonio, Barbarini, Giorgio, Barlattani, Angelo, Cariti, Giuseppe, Cozzolongo, Raffaele, Fimiani, Basilio, Francavilla, Ruggiero, Furlan, Caterina, Garrucciu, Giovanni, Iovinella, Vincenzo, Rinaldi, Luca, Marignani, Massimo, Begini, Paola, Palitti, Valeria Pace, Pellicelli, Adriano M, Scifo, Gaetano, Facciorusso, Antonio, Giacomelli, Luca, Shah, Aashni, Bertino, Gaetano, Perazzo, Serena, Bresci, Giampaolo, Izzi, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioExcel Publishing Ltd 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7747789/
https://www.ncbi.nlm.nih.gov/pubmed/33408749
http://dx.doi.org/10.7573/dic.2020-4-11

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7747789/
https://www.ncbi.nlm.nih.gov/pubmed/33408749
http://dx.doi.org/10.7573/dic.2020-4-11

Ejemplares similares